TerminatedPhase 1NCT00418132

Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic Sclerosis

Studying Diffuse cutaneous systemic sclerosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
NYU Langone Health
Principal Investigator
Stephen J. Oliver, MD
NYU Langone Health
Intervention
Thalidomide(drug)
Enrollment
30 enrolled
Eligibility
18-65 years · All sexes
Timeline
20002007

Study locations (1)

Collaborators

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00418132 on ClinicalTrials.gov

Other trials for Diffuse cutaneous systemic sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Diffuse cutaneous systemic sclerosis

← Back to all trials